Organogenesis (NASDAQ:ORGO) Q4 results:
Revenue: $74.6M (+16.8%); Advanced Would Care: $63.4M (+16.1%); Surgical & Sports Medicine: $11.3M (+25.6%).
Increase in AWC due to execution of additional
sales reps, PuraPly regaining pass-through reimbursement and growth in
amniotic products.
Net loss: ($4.4M); loss/share: ($0.04); non-GAAP EBITDA: $0.8M (+728.6%).
Cash flow ops (full year): ($33.5M) (+44.7%).
2020 guidance: Revenue: $273M –
277M (consensus: $271.4M); AWC: $229M – 231M; Surgical & Sports Med:
$44M – 46M; PurePly sales: $118M – 120M.
Shares up 26% after hours.
https://seekingalpha.com/news/3549936-organogenesis-up-26-after-hours-on-q4-beat
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.